Fax: (713) 792-5529
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma†
Article first published online: 27 MAR 2006
Copyright © 2006 American Cancer Society
Volume 106, Issue 9, pages 1925–1932, 1 May 2006
How to Cite
Rosen, D. G., Yang, G., Deavers, M. T., Malpica, A., Kavanagh, J. J., Mills, G. B. and Liu, J. (2006), Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer, 106: 1925–1932. doi: 10.1002/cncr.21767
Presented in part at a poster session at the 93rd USCAP annual meeting, Washington, D.C., March 6–12, 2004.
- Issue published online: 18 APR 2006
- Article first published online: 27 MAR 2006
- Manuscript Accepted: 26 OCT 2005
- Manuscript Revised: 20 SEP 2005
- Manuscript Received: 16 MAY 2005
- American Cancer Society Research Scholar Grant. Grant Number: RSG-04-028-1-CCE
- National Cancer Institute grant. Grant Number: P01 CA 64602-1
- prognostic marker;
- microarray analysis
Cyclins, cyclin dependent kinases (cdks), and their inhibitors act in combination to regulate progression through the cell cycle and often are dysregulated in carcinoma. The authors hypothesized that cyclin E plays an important role in ovarian carcinogenesis and that its overexpression may be an indicator of a poor prognosis.
Immunohistochemical analysis of cyclin E expression was performed by image analysis in normal ovaries, cystadenomas, tumors of low malignant potential, and 405 primary ovarian carcinomas by using tissue microarray technology.
Overexpression of cyclin E was found in 63.2% of the samples and was associated with clear cell, poorly differentiated, and serous carcinoma (P ≤ .001), high-grade tumors (P ≤ .001), late-stage disease (P = .002), age older than 60 years at the time of diagnosis (P = .04), and suboptimal cytoreduction (P = .001). A high percentage of cyclin E-expressing cells was associated with a poor outcome in univariate and in multivariate analyses. In addition, cyclin E levels also reduced survival in the late-stage disease group and in patients who underwent suboptimal debulking.
Cyclin E was identified as an independent prognostic factor in patients with ovarian carcinoma. The accumulation of cyclin E protein may be a late event in tumorigenesis and may contribute to disease progression in these patients. Cancer 2006. © 2006 American Cancer Society.